Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2NCT02954991
Official study title

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Study summary

The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedGlesatinib and Sitravatinib

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 22, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?25 U.S. locations

Locations may change over time.

Who runs it?Mirati Therapeutics Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Mirati Therapeutics Inc.
Interventions being studied
Drug: Glesatinib; Drug: Sitravatinib; Drug: Mocetinostat; Drug: Nivolumab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of non-small cell lung cancer.
  • Prior treatment with a checkpoint inhibitor (as appropriate per cohort)
  • Adequate bone marrow and organ function
Reasons someone may not be able to joinExclusion criteria
  • Uncontrolled tumor in the brain
  • Unacceptable toxicity with prior checkpoint inhibitor
  • Impaired heart function

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Yuma Regional Medical CenterYuma, Arizona
  • Beverly Hills Cancer CenterBeverly Hills, California
  • City of Hope National Medical CenterDuarte, California
  • University of California San DiegoLa Jolla, California
  • University of California San Francisco Comprehensive Cancer CenterSan Francisco, California
  • University of California Los Angeles - Torrance - Community Cancer CareSanta Clarita, California
  • Rocky Mountain Cancer Centers - Denver - MidtownDenver, Colorado
  • Baptist HealthLouisville, Kentucky
  • Henry Ford HospitalDetroit, Michigan
  • Minnesota Oncology Hematology, P.A.Minneapolis, Minnesota
  • University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
  • Saint Francis Cancer Treatment CenterGrand Island, Nebraska

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 22, 2024. Always confirm current availability with the study team.

View original record ↗